Naoki Misumida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naoki Misumida has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Yumiko Kanei
Department of Cardiology, Mount Sinai Beth Israel, New York, USA
16 shared publications- Ahmed Abdel-Latif
Division of Cardiology, Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48105, USA
12 shared publications Akihiro Kobayashi
Banner University Medical Center Phoenix, Department of Cardiology, Phoenix, AZ, USA
9 shared publications- Akihiro Kobayashi
Department of Internal Medicine, Mount Sinai Beth Israel, New York, USA
9 shared publications John Fox
8 shared publications- Yumiko Kanei
Division of Cardiology, Department of Medicine, Beth Israel Medical Center, New York, NY 10003, USA
8 shared publications
Latest Publications
- 11 March 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (5) , 693-695
Big Picture of TAVR in Small Annuli
- 11 March 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (5) , 693-695
Big Picture of TAVR in Small Annuli
- 29 December 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (2) , 340-347
Transcatheter edge‐to‐edge mitral valve repair for mitral regurgitation in patients with cardiogenic shock: A systematic review and meta‐analysis
Background: There is currently little evidence for transcatheter edge‐to‐edge mitral valve repair (TEER) for mitral regurgitation (MR) in patients with cardiogenic shock (CS). Therefore, this study investigated the characteristics and outcomes of CS patients who underwent TEER for MR.Methods: PubMed, EMBASE were searched in July 2023. Case series and observational studies reporting clinical characteristics and outcomes in CS patients with MR who underwent TEER were included. We performed a one‐group meta‐analysis using a random effects model.Results: A total of 4060 patients from 7 case series and 5 observational studies were included. The mean age was 68.2 (95% confidence interval [CI]: 64.1–72.2) years, and 41.4% of patients (95% CI: 39.1%–43.7%) were female. Pre‐TEER, severe MR was present in 85.3% (95% CI: 76.1%–91.3%) of patients. Mean left ventricular ejection fraction was 36.7% (95% CI: 29.2%–44.2%), and 54.6% (95% CI: 36.9%–71.2%) of patients received mechanical circulatory support. The severity of MR post‐TEER was less than 2+ in 88% (95% CI: 87%–89%) of patients. In‐hospital mortality was 11% (95% CI: 10%–13%), whereas 30‐day and 1‐year mortality rates were 15% (95% CI: 13%–16%), and 36% (95% CI: 21%–54%), respectively.Conclusions: This systematic review and meta‐analysis assessed the clinical characteristics and outcomes of TEER in CS patients with MR. TEER for MR in patients with CS has been successful in reducing MR in most of the patients, but with a high mortality rate. Randomized controlled trials of TEER for MR and CS are needed.
- 29 December 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 103 (2) , 340-347
Transcatheter edge‐to‐edge mitral valve repair for mitral regurgitation in patients with cardiogenic shock: A systematic review and meta‐analysis
Background: There is currently little evidence for transcatheter edge‐to‐edge mitral valve repair (TEER) for mitral regurgitation (MR) in patients with cardiogenic shock (CS). Therefore, this study investigated the characteristics and outcomes of CS patients who underwent TEER for MR.Methods: PubMed, EMBASE were searched in July 2023. Case series and observational studies reporting clinical characteristics and outcomes in CS patients with MR who underwent TEER were included. We performed a one‐group meta‐analysis using a random effects model.Results: A total of 4060 patients from 7 case series and 5 observational studies were included. The mean age was 68.2 (95% confidence interval [CI]: 64.1–72.2) years, and 41.4% of patients (95% CI: 39.1%–43.7%) were female. Pre‐TEER, severe MR was present in 85.3% (95% CI: 76.1%–91.3%) of patients. Mean left ventricular ejection fraction was 36.7% (95% CI: 29.2%–44.2%), and 54.6% (95% CI: 36.9%–71.2%) of patients received mechanical circulatory support. The severity of MR post‐TEER was less than 2+ in 88% (95% CI: 87%–89%) of patients. In‐hospital mortality was 11% (95% CI: 10%–13%), whereas 30‐day and 1‐year mortality rates were 15% (95% CI: 13%–16%), and 36% (95% CI: 21%–54%), respectively.Conclusions: This systematic review and meta‐analysis assessed the clinical characteristics and outcomes of TEER in CS patients with MR. TEER for MR in patients with CS has been successful in reducing MR in most of the patients, but with a high mortality rate. Randomized controlled trials of TEER for MR and CS are needed.
- 14 August 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (4) , 751-760
Outcomes of transcatheter edge‐to‐edge repair for atrial functional mitral regurgitation: A meta‐analysis of observational studies
Background: Transcatheter edge‐to‐edge repair (TEER) may have potential benefits in the treatment of atrial functional mitral regurgitation (AFMR), but robust evidence is currently lacking. We conducted a systematic review and meta‐analysis to investigate the clinical outcomes of TEER for AFMR, including comparisons to ventricular functional MR (VFMR).Methods: MEDLINE and EMBASE were searched through January 2023 to identify studies eligible for analysis. The primary outcome was postprocedural MR severity. Postprocedural New York Heart Association (NYHA) functional class classification and all‐cause mortality were also evaluated. Outcomes were stratified into short term (postprocedure to 6 months) and long term (6 months to 2 years).Results: A total of eight observational studies met the inclusion criteria, enrolling 539 AFMR and 3486 VFMR patients. Postprocedural MR grade ≤2 in the AFMR group was observed in 93.7% (454/491 patients; 95% confidence interval (CI), 91.1%–96.2%, I2 = 24.3%) and 97.1% (89/93 patients; 95% CI, 92.9%–100%, I2 = 26.4%) in short‐ and long‐term follow‐up, respectively. There was no difference in the rates of postprocedural MR grade ≤2 between AFMR and VFMR either in short‐term (risk ratio [RR], 1.00 [95% CI, 0.95–1.06]; p = 0.90; I2 = 53%) or long‐term follow‐up (RR, 1.08 [95% CI, 0.89–1.32]; p = 0.44; I2 = 22%). Similarly, no difference was observed between AFMR and VFMR in the rates of postprocedural NYHA class ≤2 or all‐cause mortality.Conclusion: TEER provides similar clinical outcomes for AFMR and VFMR. A high rate of MR grade ≤2 was observed in patients at both short‐ and long‐term follow‐ups. Further prospective studies with TEER versus medical therapy and/or rhythm control for AFMR are warranted.
- 14 August 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (4) , 751-760
Outcomes of transcatheter edge‐to‐edge repair for atrial functional mitral regurgitation: A meta‐analysis of observational studies
Background: Transcatheter edge‐to‐edge repair (TEER) may have potential benefits in the treatment of atrial functional mitral regurgitation (AFMR), but robust evidence is currently lacking. We conducted a systematic review and meta‐analysis to investigate the clinical outcomes of TEER for AFMR, including comparisons to ventricular functional MR (VFMR).Methods: MEDLINE and EMBASE were searched through January 2023 to identify studies eligible for analysis. The primary outcome was postprocedural MR severity. Postprocedural New York Heart Association (NYHA) functional class classification and all‐cause mortality were also evaluated. Outcomes were stratified into short term (postprocedure to 6 months) and long term (6 months to 2 years).Results: A total of eight observational studies met the inclusion criteria, enrolling 539 AFMR and 3486 VFMR patients. Postprocedural MR grade ≤2 in the AFMR group was observed in 93.7% (454/491 patients; 95% confidence interval (CI), 91.1%–96.2%, I2 = 24.3%) and 97.1% (89/93 patients; 95% CI, 92.9%–100%, I2 = 26.4%) in short‐ and long‐term follow‐up, respectively. There was no difference in the rates of postprocedural MR grade ≤2 between AFMR and VFMR either in short‐term (risk ratio [RR], 1.00 [95% CI, 0.95–1.06]; p = 0.90; I2 = 53%) or long‐term follow‐up (RR, 1.08 [95% CI, 0.89–1.32]; p = 0.44; I2 = 22%). Similarly, no difference was observed between AFMR and VFMR in the rates of postprocedural NYHA class ≤2 or all‐cause mortality.Conclusion: TEER provides similar clinical outcomes for AFMR and VFMR. A high rate of MR grade ≤2 was observed in patients at both short‐ and long‐term follow‐ups. Further prospective studies with TEER versus medical therapy and/or rhythm control for AFMR are warranted.
- 1 October 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (7) , E992-E1001
Hemodynamic response to transseptal transcatheter mitral valve replacement in patients with severe mitral stenosis due to severe mitral annular calcification
Objectives: We aimed to investigate the invasive hemodynamic changes with transcatheter mitral valve replacement (TMVR) in patients with severe mitral stenosis due to severe mitral annular calcification.Background: The hemodynamic response to TMVR in patients with mitral stenosis related to degenerative mitral annular calcification has not been fully elucidated.Methods: We conducted retrospective review of patients who underwent successful transseptal TMVR with balloon‐expandable valves for symptomatic severe mitral stenosis due to mitral annular calcification at our institution between January 2014 and February 2020. Invasive hemodynamic measurements were obtained both before valve implantation (predeployment) and after (postdeployment).Results: Eighteen patients (age 72 ± 10 years, 44% female) were included for the analysis. There was a significant reduction in mean left atrial pressure (23.7 ± 5.6 mmHg versus 20.6 ± 4.8 mmHg; p = .01), left atrial v‐wave (mean 39.3 ± 10.2 mmHg versus 32.9 ± 9.9 mmHg; p = .01), and an increase in systemic mean blood pressure (72.6 mmHg ±11.2 versus 79.5 ± 9.9 mmHg; p = .02) postdeployment compared to predeployment. Patients who had symptom improvement at 30‐day follow‐up tended to have greater reduction in mean left atrial pressure (4.4 ± 4.4 mmHg versus 0.5 ± 5.2 mmHg; p = .16) and v‐wave (8.6 ± 9.0 mmHg versus 0.7 ± 8.4 mmHg; p = .10) compared to those who did not experience improvement of symptoms.Conclusions: Transseptal TMVR for severe mitral stenosis due to mitral annular calcification is associated with reductions in mean left atrial pressure and left atrial v‐wave, and an increase in systemic arterial pressure.
- 1 October 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (7) , E992-E1001
Hemodynamic response to transseptal transcatheter mitral valve replacement in patients with severe mitral stenosis due to severe mitral annular calcification
Objectives: We aimed to investigate the invasive hemodynamic changes with transcatheter mitral valve replacement (TMVR) in patients with severe mitral stenosis due to severe mitral annular calcification.Background: The hemodynamic response to TMVR in patients with mitral stenosis related to degenerative mitral annular calcification has not been fully elucidated.Methods: We conducted retrospective review of patients who underwent successful transseptal TMVR with balloon‐expandable valves for symptomatic severe mitral stenosis due to mitral annular calcification at our institution between January 2014 and February 2020. Invasive hemodynamic measurements were obtained both before valve implantation (predeployment) and after (postdeployment).Results: Eighteen patients (age 72 ± 10 years, 44% female) were included for the analysis. There was a significant reduction in mean left atrial pressure (23.7 ± 5.6 mmHg versus 20.6 ± 4.8 mmHg; p = .01), left atrial v‐wave (mean 39.3 ± 10.2 mmHg versus 32.9 ± 9.9 mmHg; p = .01), and an increase in systemic mean blood pressure (72.6 mmHg ±11.2 versus 79.5 ± 9.9 mmHg; p = .02) postdeployment compared to predeployment. Patients who had symptom improvement at 30‐day follow‐up tended to have greater reduction in mean left atrial pressure (4.4 ± 4.4 mmHg versus 0.5 ± 5.2 mmHg; p = .16) and v‐wave (8.6 ± 9.0 mmHg versus 0.7 ± 8.4 mmHg; p = .10) compared to those who did not experience improvement of symptoms.Conclusions: Transseptal TMVR for severe mitral stenosis due to mitral annular calcification is associated with reductions in mean left atrial pressure and left atrial v‐wave, and an increase in systemic arterial pressure.
- Open Access
- 18 September 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (6) , 4320-4325
Edge-to-Edge Tricuspid Valve Repair for Severe Tricuspid Regurgitation 20 Years After Cardiac Transplantation
Tricuspid valve regurgitation in orthotopic heart transplant recipients is common. Surgical corrections have been the mainstay of the treatment for diuretic-refractory heart failure due to severe tricuspid regurgitation. However, post-transplant patients inherently carry higher surgical risk owing to previous sternotomy and immunocompromised state. We report a case of successful percutaneous edge-to-edge tricuspid valve repair for severe tricuspid regurgitation after cardiac transplantation. A 27-year-old man with a history of idiopathic restrictive cardiomyopathy status after orthotopic heart transplant presented with severe right-sided heart failure symptoms. A transthoracic echocardiogram showed bi-atrial enlargement and moderate-to-severe tricuspid regurgitation, and an increase to the severe range with exercise. Percutaneous edge-to-edge tricuspid valve repair was performed. The patient's symptoms improved, and follow-up echocardiogram showed mild tricuspid regurgitation. Percutaneous tricuspid valve repair can be considered as an alternative option to conventional surgery for symptomatic severe tricuspid regurgitation in orthotopic heart transplant recipients with suitable anatomy.
- 18 September 2020
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (6) , 4320-4325
Open AccessEdge-to-Edge Tricuspid Valve Repair for Severe Tricuspid Regurgitation 20 Years After Cardiac Transplantation
Tricuspid valve regurgitation in orthotopic heart transplant recipients is common. Surgical corrections have been the mainstay of the treatment for diuretic-refractory heart failure due to severe tricuspid regurgitation. However, post-transplant patients inherently carry higher surgical risk owing to previous sternotomy and immunocompromised state. We report a case of successful percutaneous edge-to-edge tricuspid valve repair for severe tricuspid regurgitation after cardiac transplantation. A 27-year-old man with a history of idiopathic restrictive cardiomyopathy status after orthotopic heart transplant presented with severe right-sided heart failure symptoms. A transthoracic echocardiogram showed bi-atrial enlargement and moderate-to-severe tricuspid regurgitation, and an increase to the severe range with exercise. Percutaneous edge-to-edge tricuspid valve repair was performed. The patient's symptoms improved, and follow-up echocardiogram showed mild tricuspid regurgitation. Percutaneous tricuspid valve repair can be considered as an alternative option to conventional surgery for symptomatic severe tricuspid regurgitation in orthotopic heart transplant recipients with suitable anatomy.
- 30 April 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (5) , E552-E556
Antegrade transseptal transcatheter aortic valve replacement: Back to the future?
Antegrade transseptal approach was utilized in the first human case of transcatheter aortic valve replacement (TAVR) and in the early phase of TAVR. Various challenges with the antegrade transseptal approach including procedural complexity, need for atrial septal crossing, and potential for injury to the mitral valve apparatus led it to being supplanted by other approaches. These challenges have now largely been mitigated as structural interventionalists routinely perform left atrial procedures. We report a case of antegrade transseptal TAVR using a large bore sheath placed in the mid left ventricle across the mitral orifice to protect the mitral valve apparatus and facilitate valve deployment. An 84‐year‐old man with heart failure symptoms was seen for severe aortic stenosis. The severity of peripheral arterial disease precluded femoral, axillary, carotid, or transcaval routes. After transseptal puncture and creation of an arteriovenous rail, a long 26‐Fr sheath was advanced from the right femoral vein transseptally over the arteriovenous rail, past the mitral valve inflow to the mid left ventricular cavity. The sheath provided a stable platform with stable intraprocedure hemodynamics. Balloon valvuloplasty was performed in an antegrade manner, after which a 29‐mm SAPIEN S3 prosthesis was advanced into the aortic valve position and deployed under rapid pacing. We observed no injury to the mitral leaflets or subvalvular apparatus after the procedure. The antegrade transseptal approach should be revisited as an option for patients at high surgical risk with no other suitable access site. The use of a large bore sheath facilitates this approach.
- 30 April 2020
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 96 (5) , E552-E556
Antegrade transseptal transcatheter aortic valve replacement: Back to the future?
Antegrade transseptal approach was utilized in the first human case of transcatheter aortic valve replacement (TAVR) and in the early phase of TAVR. Various challenges with the antegrade transseptal approach including procedural complexity, need for atrial septal crossing, and potential for injury to the mitral valve apparatus led it to being supplanted by other approaches. These challenges have now largely been mitigated as structural interventionalists routinely perform left atrial procedures. We report a case of antegrade transseptal TAVR using a large bore sheath placed in the mid left ventricle across the mitral orifice to protect the mitral valve apparatus and facilitate valve deployment. An 84‐year‐old man with heart failure symptoms was seen for severe aortic stenosis. The severity of peripheral arterial disease precluded femoral, axillary, carotid, or transcaval routes. After transseptal puncture and creation of an arteriovenous rail, a long 26‐Fr sheath was advanced from the right femoral vein transseptally over the arteriovenous rail, past the mitral valve inflow to the mid left ventricular cavity. The sheath provided a stable platform with stable intraprocedure hemodynamics. Balloon valvuloplasty was performed in an antegrade manner, after which a 29‐mm SAPIEN S3 prosthesis was advanced into the aortic valve position and deployed under rapid pacing. We observed no injury to the mitral leaflets or subvalvular apparatus after the procedure. The antegrade transseptal approach should be revisited as an option for patients at high surgical risk with no other suitable access site. The use of a large bore sheath facilitates this approach.
- 1 July 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 124 (2) , 321-322
Characteristics, Outcomes, and Predictors of Significant Pericardial Complications in Patients who Underwent Transcatheter Aortic Valve Implantation
- 1 July 2019
- Published by Elsevier in The American Journal of Cardiology
- Vol. 124 (2) , 321-322
Characteristics, Outcomes, and Predictors of Significant Pericardial Complications in Patients who Underwent Transcatheter Aortic Valve Implantation
- 10 April 2019
- Published by Springer Nature in Current Cardiology Reports
- Vol. 21 (5) , 39
Revascularization Strategies for Non-ST-Elevation Myocardial Infarction
Non-ST-elevation myocardial infarction (NSTEMI) is an urgent medical condition that requires prompt application of simultaneous pharmacologic and non-pharmacologic therapies. The variation in patient clinical characteristics coupled with the multitude of treatment modalities makes optimal and timely management challenging. This review summarizes risk stratification of patients, the role and timing of revascularization, and highlights important considerations in the revascularization approach with attention to individual patient characteristics.
- 10 April 2019
- Published by Springer Nature in Current Cardiology Reports
- Vol. 21 (5) , 39
Revascularization Strategies for Non-ST-Elevation Myocardial Infarction
Non-ST-elevation myocardial infarction (NSTEMI) is an urgent medical condition that requires prompt application of simultaneous pharmacologic and non-pharmacologic therapies. The variation in patient clinical characteristics coupled with the multitude of treatment modalities makes optimal and timely management challenging. This review summarizes risk stratification of patients, the role and timing of revascularization, and highlights important considerations in the revascularization approach with attention to individual patient characteristics.